Jia joined ACEA Therapeutics in 2010 and is the head of the formulation and analytical department, and has over 20 years of pharmaceutical research and development experience.

Prior to joining ACEA, Jia was the PharmaSci CMC project leader at Pfizer, Inc., where she managed over 25 projects，and brought several therapeutics from early discovery to Phase I/II development. Several drugs that Jia has helped develop have gained great commercial success, such as Xalkori® (crizotinib) and Inlyta® (axitinib). As a formulation and analytics expert, she has served as a member of several Pfizer global innovation committees, such as nano-technology, spray-dry dispersion (SDD), polymorphism/salt selections, and high-throughput method development. She has also been appointed to Pfizer’s global portfolio committee, as well as their due diligence team.

Jia began her career in the US with Agouron Pharmaceuticals, where she was involved in the development and launch of Viracept®. She has also worked as a senior consultant at Frontier Biotechnologies in China, and led the formulation/analytical development of long-lasting HIV fusion-inhibitor “Albuvirtide”, which was recently approved by CFDA and is ready for commercialization. Before coming to the US, Jia was a quality control manager at Xian-Janssen Pharmaceuticals (J&J).

Jia received her M.S. degree in pharmaceutics from University of Minnesota and her M.B.A. from University of Phoenix.